Singapore, March 27 -- Merck, known as MSD outside of the United States and Canada, and Jiangsu Hengrui Pharmaceuticals Co., a global pharmaceutical company focused on scientific and technological innovation, have entered into an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a Phase 2 clinical trial in China.

"Elevated blood concentrations of Lp(a) provides a well-documented risk factor for atherosclerotic cardiovascular disease, affecting as many as 1 in 5 adults globally," said Dr Dean Y. Li, president, Merck Research Laboratories. "HRS-5346, an investigational oral small molecule inhibitor of Lp(a) formation, is an important addition th...